Concepts (156)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinsonian Disorders | 5 | 2023 | 91 | 2.170 |
Why?
|
| Intracranial Arteriosclerosis | 2 | 2022 | 29 | 1.380 |
Why?
|
| Stroke | 6 | 2021 | 117 | 1.120 |
Why?
|
| Brain | 6 | 2023 | 707 | 1.090 |
Why?
|
| Aged | 21 | 2023 | 4000 | 0.980 |
Why?
|
| Aging | 7 | 2023 | 680 | 0.940 |
Why?
|
| Aged, 80 and over | 14 | 2023 | 2152 | 0.840 |
Why?
|
| Disabled Persons | 2 | 2023 | 47 | 0.820 |
Why?
|
| Alzheimer Disease | 3 | 2023 | 800 | 0.780 |
Why?
|
| Brain Ischemia | 4 | 2017 | 35 | 0.770 |
Why?
|
| Independent Living | 2 | 2021 | 137 | 0.740 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 22 | 0.730 |
Why?
|
| Gait | 1 | 2023 | 195 | 0.670 |
Why?
|
| Longitudinal Studies | 9 | 2023 | 651 | 0.670 |
Why?
|
| Female | 22 | 2023 | 6974 | 0.660 |
Why?
|
| Male | 21 | 2023 | 6815 | 0.660 |
Why?
|
| Mobility Limitation | 1 | 2021 | 36 | 0.650 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2021 | 57 | 0.640 |
Why?
|
| Dementia | 1 | 2023 | 236 | 0.640 |
Why?
|
| Humans | 25 | 2023 | 12240 | 0.640 |
Why?
|
| Exercise | 2 | 2023 | 233 | 0.570 |
Why?
|
| Prefrontal Cortex | 2 | 2023 | 66 | 0.550 |
Why?
|
| Cerebral Hemorrhage | 4 | 2017 | 37 | 0.550 |
Why?
|
| Sex Characteristics | 1 | 2018 | 64 | 0.540 |
Why?
|
| Upper Extremity | 1 | 2017 | 10 | 0.520 |
Why?
|
| Transcranial Direct Current Stimulation | 1 | 2017 | 5 | 0.520 |
Why?
|
| Motor Activity | 2 | 2017 | 175 | 0.500 |
Why?
|
| Incidence | 6 | 2021 | 338 | 0.490 |
Why?
|
| Neuropsychological Tests | 2 | 2015 | 558 | 0.480 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2015 | 9 | 0.470 |
Why?
|
| Dementia, Vascular | 1 | 2015 | 19 | 0.460 |
Why?
|
| Aspirin | 1 | 2015 | 20 | 0.450 |
Why?
|
| Parkinson Disease | 3 | 2023 | 314 | 0.360 |
Why?
|
| Iran | 6 | 2017 | 10 | 0.340 |
Why?
|
| Autopsy | 3 | 2021 | 174 | 0.340 |
Why?
|
| Risk Factors | 5 | 2021 | 1049 | 0.330 |
Why?
|
| Middle Aged | 11 | 2018 | 4043 | 0.270 |
Why?
|
| Adult | 10 | 2021 | 3557 | 0.270 |
Why?
|
| Activities of Daily Living | 2 | 2023 | 182 | 0.270 |
Why?
|
| Metabolic Syndrome | 2 | 2018 | 40 | 0.250 |
Why?
|
| Stroke Rehabilitation | 1 | 2006 | 8 | 0.240 |
Why?
|
| Language | 1 | 2006 | 30 | 0.240 |
Why?
|
| Hospitalization | 1 | 2007 | 158 | 0.240 |
Why?
|
| Cardiovascular Diseases | 3 | 2018 | 166 | 0.230 |
Why?
|
| Hypertension | 2 | 2016 | 85 | 0.210 |
Why?
|
| Surveys and Questionnaires | 1 | 2006 | 546 | 0.200 |
Why?
|
| Cohort Studies | 4 | 2020 | 827 | 0.190 |
Why?
|
| Hand Strength | 1 | 2023 | 24 | 0.190 |
Why?
|
| Age Factors | 2 | 2021 | 350 | 0.190 |
Why?
|
| Disease Progression | 2 | 2021 | 290 | 0.180 |
Why?
|
| Walking | 1 | 2023 | 108 | 0.180 |
Why?
|
| Spastic Paraplegia, Hereditary | 1 | 2021 | 1 | 0.180 |
Why?
|
| Motor Cortex | 1 | 2021 | 9 | 0.180 |
Why?
|
| Time Factors | 2 | 2017 | 695 | 0.170 |
Why?
|
| Treatment Outcome | 3 | 2021 | 1478 | 0.170 |
Why?
|
| Sodium | 1 | 2021 | 33 | 0.170 |
Why?
|
| Potassium | 1 | 2021 | 32 | 0.170 |
Why?
|
| TDP-43 Proteinopathies | 1 | 2021 | 40 | 0.160 |
Why?
|
| Cerebrovascular Disorders | 1 | 2021 | 60 | 0.160 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 161 | 0.150 |
Why?
|
| Life Style | 1 | 2020 | 102 | 0.150 |
Why?
|
| Prospective Studies | 4 | 2023 | 817 | 0.140 |
Why?
|
| Chi-Square Distribution | 1 | 2018 | 60 | 0.140 |
Why?
|
| Arteriolosclerosis | 1 | 2018 | 25 | 0.140 |
Why?
|
| Chicago | 1 | 2020 | 453 | 0.140 |
Why?
|
| Canada | 2 | 2015 | 21 | 0.140 |
Why?
|
| tau Proteins | 1 | 2018 | 88 | 0.140 |
Why?
|
| alpha-Synuclein | 1 | 2018 | 59 | 0.130 |
Why?
|
| Menopause | 1 | 2018 | 41 | 0.130 |
Why?
|
| Apolipoprotein E4 | 1 | 2018 | 106 | 0.130 |
Why?
|
| Cognitive Dysfunction | 1 | 2023 | 449 | 0.130 |
Why?
|
| Nonlinear Dynamics | 1 | 2017 | 6 | 0.130 |
Why?
|
| DNA-Binding Proteins | 1 | 2018 | 151 | 0.130 |
Why?
|
| CADASIL | 1 | 2017 | 1 | 0.130 |
Why?
|
| Triglycerides | 1 | 2017 | 24 | 0.130 |
Why?
|
| Waist Circumference | 1 | 2017 | 23 | 0.130 |
Why?
|
| Feasibility Studies | 1 | 2017 | 113 | 0.130 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 400 | 0.130 |
Why?
|
| Disability Evaluation | 1 | 2017 | 105 | 0.130 |
Why?
|
| Recovery of Function | 1 | 2017 | 118 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 182 | 0.120 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 27 | 0.120 |
Why?
|
| Tropanes | 1 | 2015 | 1 | 0.120 |
Why?
|
| Organotechnetium Compounds | 1 | 2015 | 6 | 0.120 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2015 | 37 | 0.110 |
Why?
|
| Incidental Findings | 1 | 2014 | 6 | 0.100 |
Why?
|
| Case-Control Studies | 3 | 2021 | 256 | 0.100 |
Why?
|
| Follow-Up Studies | 2 | 2013 | 726 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 324 | 0.080 |
Why?
|
| Body Mass Index | 2 | 2023 | 221 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2021 | 295 | 0.070 |
Why?
|
| Efferent Pathways | 1 | 2008 | 1 | 0.070 |
Why?
|
| Neural Conduction | 1 | 2008 | 4 | 0.070 |
Why?
|
| Action Potentials | 1 | 2008 | 64 | 0.070 |
Why?
|
| Age Distribution | 1 | 2007 | 25 | 0.070 |
Why?
|
| Skin | 1 | 2008 | 73 | 0.070 |
Why?
|
| Middle East | 2 | 2017 | 3 | 0.060 |
Why?
|
| Diabetes Complications | 2 | 2017 | 28 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2017 | 115 | 0.060 |
Why?
|
| Interviews as Topic | 1 | 2006 | 66 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 100 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 423 | 0.050 |
Why?
|
| Adaptor Protein Complex 1 | 1 | 2023 | 4 | 0.050 |
Why?
|
| Adaptor Protein Complex beta Subunits | 1 | 2023 | 4 | 0.050 |
Why?
|
| Proteome | 1 | 2023 | 13 | 0.050 |
Why?
|
| Amyloid beta-Peptides | 1 | 2023 | 98 | 0.050 |
Why?
|
| Muscle Spasticity | 1 | 2021 | 1 | 0.040 |
Why?
|
| Lower Extremity | 1 | 2021 | 7 | 0.040 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2021 | 8 | 0.040 |
Why?
|
| Potassium, Dietary | 1 | 2021 | 1 | 0.040 |
Why?
|
| Sodium, Dietary | 1 | 2021 | 3 | 0.040 |
Why?
|
| Causality | 1 | 2021 | 22 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2021 | 125 | 0.040 |
Why?
|
| Comorbidity | 1 | 2021 | 209 | 0.040 |
Why?
|
| Age of Onset | 1 | 2018 | 46 | 0.030 |
Why?
|
| United States | 1 | 2021 | 989 | 0.030 |
Why?
|
| Microvessels | 1 | 2017 | 11 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2017 | 105 | 0.030 |
Why?
|
| Overweight | 1 | 2017 | 35 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 141 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2017 | 40 | 0.030 |
Why?
|
| Apolipoproteins B | 1 | 2016 | 1 | 0.030 |
Why?
|
| Apolipoprotein A-I | 1 | 2016 | 1 | 0.030 |
Why?
|
| Australia | 1 | 2016 | 8 | 0.030 |
Why?
|
| Waist-Hip Ratio | 1 | 2016 | 5 | 0.030 |
Why?
|
| International Cooperation | 1 | 2016 | 7 | 0.030 |
Why?
|
| Asia | 1 | 2016 | 6 | 0.030 |
Why?
|
| Africa | 1 | 2016 | 7 | 0.030 |
Why?
|
| Europe | 1 | 2016 | 21 | 0.030 |
Why?
|
| China | 1 | 2016 | 25 | 0.030 |
Why?
|
| Obesity, Abdominal | 1 | 2016 | 11 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2016 | 28 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2016 | 40 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 78 | 0.030 |
Why?
|
| Health Behavior | 1 | 2016 | 74 | 0.030 |
Why?
|
| Self Report | 1 | 2016 | 94 | 0.030 |
Why?
|
| Smoking | 1 | 2016 | 84 | 0.030 |
Why?
|
| Obesity | 1 | 2017 | 156 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 78 | 0.030 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 57 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 151 | 0.030 |
Why?
|
| Biomarkers | 1 | 2016 | 294 | 0.030 |
Why?
|
| Prevalence | 1 | 2014 | 175 | 0.020 |
Why?
|
| Rural Health | 1 | 2013 | 3 | 0.020 |
Why?
|
| Angina, Unstable | 1 | 2013 | 5 | 0.020 |
Why?
|
| Urban Health | 1 | 2013 | 8 | 0.020 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2013 | 6 | 0.020 |
Why?
|
| Health Surveys | 1 | 2013 | 38 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2013 | 64 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2011 | 60 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 73 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2008 | 35 | 0.020 |
Why?
|
| Electrophysiology | 1 | 2008 | 74 | 0.020 |
Why?
|
| Hand | 1 | 2008 | 24 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2011 | 437 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2008 | 152 | 0.020 |
Why?
|